BRIEF published on 11/26/2024 at 17:50, 25 days 1 hour ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
PRESS RELEASE published on 11/26/2024 at 17:45, 25 days 1 hour ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
BRIEF published on 10/30/2024 at 17:50, 1 month 22 days ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
BRIEF published on 10/07/2024 at 17:50, 2 months 14 days ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
BRIEF published on 09/06/2024 at 17:50, 3 months 15 days ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 3 months 15 days ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 3 months 17 days ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 3 months 17 days ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 3 months 23 days ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 5 months 3 days ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
Published on 12/21/2024 at 01:30, 17 hours 48 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 48 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 13 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 48 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 27 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 33 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 7 hours 1 minute ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
